Modaplex FGFR Assays

The fibroblast growth factor receptor (FGFR) family consists of four signaling tyrosine kinase receptors (FGFR1-FGFR4) that interact with 18 secreted FGF proteins [1]. They are expressed in nearly all tissues and play essential roles in a wide range of physiological mechanisms [2]. Dysregulation of FGFR signaling can occur through a variety of molecular mechanisms including chromosomal translocation, mutations, and gene amplification, leading to receptor and ligand over-expression. Abnormalities of FGFs and FGFRs have been observed in many cancer types, and are reported to have different implications in various tumors [3,4].

Biotype deciphers complexity in FGFR by offering a comprehensive panel to detect genetic alterations relevant to FGFR1, FGFR2, FGFR3, FGFR4, FGF3, FGF4, and FGF19. The FGFR panel comprises four FGFR assays that are used for the detection of FGFR copy number variations, gene fusions, mutations, and gene expressions. In combination with the Modaplex technology, it is possible to detect all variations simultaneously in just five hours.

    The Modaplex FGFR Analysis Kits are:

    • developed under ISO 9001:2015 and FDA’s Design Control Guidance for medical device manufacturers
    • standardized kits with a comprehensive control concept
    • ready-to-use assays with a simple and efficient workflow
    • to be analyzed with Biotype Innovation’s Moda-RA (Modaplex Result Analyzer) software for rapid result interpretation
    • tested on archived FFPE material


    [1] D. M. Ornitz and N. Itoh, “The fibroblast growth factor signaling pathway”, Wiley Interdiscip. Rev. Dev. Biol., vol. 4, no. 3, pp. 215–266, 2015.
    [2] M. Touat, E. Ileana, S. Postel-Vinay, F. André, and J. C. Soria, “Targeting FGFR signaling in cancer”, Clin. Cancer Res., vol. 21, no. 12, pp. 2684–2694, 2015.
    [3] W. Theelen, L. Mittempergher, S. Willems, A. Bosma, D. Peters, V. van der Noort, E. Japenga, K. Koole, T. Peeters, T. Šuštić, J. Blaauwgeers, C. van Noesel, R. Bernards, and M. van den Heuvel, “FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer”, J. Pathol. Clin. Res., no. October, pp. 223–233, 2016.
    [4] J. Wesche, K. Haglund, and E. M. Haugsten, “Fibroblast growth factors and their receptors in cancer”, Biochem. J., vol. 437, no. 2, pp. 199–213, 2011.